{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:49:01Z","timestamp":1760100541873},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T00:00:00Z","timestamp":1357689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s00520-012-1705-3","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T03:44:01Z","timestamp":1357703041000},"page":"1613-1620","source":"Crossref","is-referenced-by-count":3,"title":["Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient\u2013nurse satisfaction"],"prefix":"10.1007","volume":"21","author":[{"given":"Thierry","family":"Lebret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Loup","family":"Mouysset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"El Kouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Bastit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryem","family":"Ktiouet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khemaies","family":"Slimane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Murraciole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Gu\u00e9rif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,9]]},"reference":[{"key":"1705_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1749-6632.2010.05766.x","volume":"1218","author":"R Coleman","year":"2011","unstructured":"Coleman R (2011) The use of bisphosphonates in cancer treatment. Ann N Y Acad Sci 1218:3\u201314. doi: 10.1111\/j.1749-6632.2010.05766.x","journal-title":"Ann N Y Acad Sci"},{"key":"1705_CR2","doi-asserted-by":"crossref","unstructured":"Joerger M, Gnant M (eds) (2012) Prevention of bone metastases. Recent Results Cancer Res Ser 192. doi: 10.1007\/978-3-642-21892-7","DOI":"10.1007\/978-3-642-21892-7"},{"key":"1705_CR3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cncr.25529","volume":"117","author":"R Coleman","year":"2011","unstructured":"Coleman R, Cook R, Hirsh V, Major P, Lipton A (2011) Zoledronic acid use in cancer patients: more than just supportive care? Cancer 117:11\u201323","journal-title":"Cancer"},{"key":"1705_CR4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/SPC.0b013e328349dc17","volume":"5","author":"JR Berenson","year":"2011","unstructured":"Berenson JR (2011) Antitumor effects of bisphosphonates: from the laboratory to the clinic. Curr Opin Support Palliat Care 5:233\u2013240","journal-title":"Curr Opin Support Palliat Care"},{"key":"1705_CR5","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1586\/era.11.71","volume":"11","author":"A Lipton","year":"2011","unstructured":"Lipton A (2011) Zoledronic acid: multiplicity of use across the cancer continuum. Expert Rev Anticancer Ther 11:999\u20131012","journal-title":"Expert Rev Anticancer Ther"},{"key":"1705_CR6","first-page":"CD003474","volume":"2","author":"MH Wong","year":"2012","unstructured":"Wong MH, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2:CD003474","journal-title":"Cochrane Database Syst Rev"},{"key":"1705_CR7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2011.10.021","volume":"48","author":"T Yan","year":"2012","unstructured":"Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, Shao Z, Lu J (2012) The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 48:187\u2013195","journal-title":"Eur J Cancer"},{"key":"1705_CR8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00520-004-0628-z","volume":"12","author":"B Chern","year":"2004","unstructured":"Chern B, Joseph D, Joshua D, Pittman K, Richardson G, Schou M, Lowe S, Copeman M, De Abreu LR, Lynch K (2004) Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer 12:463\u2013466","journal-title":"Support Care Cancer"},{"key":"1705_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3747\/co.v17i2.507","volume":"17","author":"HK Marr","year":"2010","unstructured":"Marr HK, Stiles CR, Boyar MA, Braun TC, Hagen NA, Janzen C, Whitten LM, Pereira JL (2010) Feasibility of administering zoledronic acid in palliative patients being cared for in the community: results of a pilot study. Curr Oncol 17:69\u201374","journal-title":"Curr Oncol"},{"key":"1705_CR10","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","volume":"92","author":"A Wardley","year":"2005","unstructured":"Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869\u20131876","journal-title":"Br J Cancer"},{"key":"1705_CR11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1179\/joc.2006.18.2.217","volume":"18","author":"A Italiano","year":"2006","unstructured":"Italiano A, Ciais C, Chamorey E, Marcy PY, Largillier R, Ferrero JM, Thyss A (2006) Home infusions of biphosphonate in cancer patients: a prospective study. J Chemother 18:217\u2013220","journal-title":"J Chemother"},{"key":"1705_CR12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.archger.2005.10.006","volume":"43","author":"A Santangelo","year":"2006","unstructured":"Santangelo A, Testai M, Barbagallo P, Manuele S, Di Stefano A, Tomarchio M, Trizzino G, Musumeci G, Panebianco P, Maugeri D (2006) The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population. Arch Gerontol Geriatr 43:187\u2013192","journal-title":"Arch Gerontol Geriatr"},{"key":"1705_CR13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/jpm.2006.0122","volume":"10","author":"D Tassinari","year":"2007","unstructured":"Tassinari D, Poggi B, Nicoletti S, Fantini M, Tamburini E, Possenti C, Sartori S (2007) Zoledronic acid treatment at home: safety data from an observational prospective trial. J Palliat Med 10:352\u2013358","journal-title":"J Palliat Med"},{"key":"1705_CR14","first-page":"26","volume":"715","author":"M Quesnel","year":"2007","unstructured":"Quesnel M (2007) Nurse\u2019s role in the home management of patients with breast cancer and bone metastases. Soins 715:26\u201328","journal-title":"Soins"},{"key":"1705_CR15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1517\/14740338.2011.540387","volume":"10","author":"R Coleman","year":"2011","unstructured":"Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, Brown J (2011) Zoledronic acid. Expert Opin Drug Saf 10:133\u2013145","journal-title":"Expert Opin Drug Saf"},{"key":"1705_CR16","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3899\/jrheum.100221","volume":"38","author":"AA Khan","year":"2011","unstructured":"Khan AA, Rios LP, S\u00e3ndor GK, Khan N, Peters E, Rahman MO, Clokie CM, Dore E, Dubois S (2011) Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 38:1396\u20131402","journal-title":"J Rheumatol"},{"key":"1705_CR17","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1185\/030079907X210543","volume":"23","author":"P Barrett-Lee","year":"2007","unstructured":"Barrett-Lee P, Bloomfield D, Dougherty L, Harries M, Laing R, Patel H, Walker M (2007) An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting. Curr Med Res Opin 23:1575\u20131582","journal-title":"Curr Med Res Opin"},{"key":"1705_CR18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejon.2011.02.006","volume":"16","author":"BT Jensen","year":"2012","unstructured":"Jensen BT, Dielenseger P, Drudge-Coates L, Flynn K, Hieronymi S, Erik van Muilekom HA, Pieters R, Voss LB (2012) Taking the lead: sharing best practice in intravenous bisphosphonate use in urological cancers. Eur J Oncol Nurs 16:42\u201353. doi: 10.1016\/j.ejon.2011.02.006","journal-title":"Eur J Oncol Nurs"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1705-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-012-1705-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1705-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T15:08:00Z","timestamp":1644073680000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-012-1705-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,9]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1007\/s00520-012-1705-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,9]]}}}